Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Pharmaceuticals Lowers 2020 Sales Expectations Due to COVID-19

By Cory Renauer - May 6, 2020 at 12:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The impact of the pandemic led the biopharmaceutical company to trim its revenue guidance for polyneuropathy treatment Onpattro.

On Wednesday, Alnylam Pharmaceuticals (ALNY 1.94%) reported first-quarter results that showed impressive sales growth for its recently launched drugs. Unfortunately, the COVID-19 pandemic has watered down the launch of its lead drug, Onpattro, and the company isn't quite as confident about its sales trajectory for the rest of the year. 

Lowering guidance 

In February, Alnylam told investors it expected that sales of Onpattro would reach between $285 million and $315 million in 2020, and the company began the year on pace to hit that range. During Q1, Onpattro sales soared 154% year over year to an annualized $267 million, but the company now expects sales will level off for the rest of the year.

Close up of person using a calculator.

Image source: Getty Images.

The anticipated impact of the COVID-19 pandemic led Alnylam to cut its forecast for 2020 Onpattro sales by 5% to a range between $270 million and $300 million. Investors will be glad to know the company has also lowered its operating expense guidance range from between $1.18 billion and $1.30 billion to a range between $1.16 billion and $1.25 billion.

Solid footing

While Alnylam is still losing money, it won't likely need to make another trip to the equity markets. The company finished March with $1.34 billion in cash on its balance sheet after burning through $182 million during the first quarter.

Sales of Alnylam's second drug to earn approval, Givlaari reached an annualized $21 million in the first quarter, which was its first full quarter post-approval. If the company does flatten its extra-comfy cash cushion, though, it can still access up to $2 billion worth of non-dilutive financing from Blackstone (BX) per a recent agreement with the giant alternative investment firm.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$233.85 (1.94%) $4.46
The Blackstone Group L.P. Stock Quote
The Blackstone Group L.P.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.